Guo He resumes & CV records
Resumes
Guo He, 55668 Salem End Rd, Framingham, MA 01702
Guo He Phones & Addresses
668 Salem End Rd, Framingham, MA 01702
Shrewsbury, MA
Andover, MA
Lexington, MA
Woburn, MA
Middletown, CT
Oak Harbor, WA
New Haven, CT
Social networks
Guo He
Linkedin
Mentions for Guo He
Publications & IP owners
Us Patents
Pyrrolopyrimidine Compounds And Their Uses
US Patent:
2010010, Apr 29, 2010
Filed:
Aug 21, 2009
Appl. No.:
12/545322
Inventors:
Gilbert Besong - Cambridge, GB
Christopher Thomas Brain - Cambridge MA, US
Clinton A. Brooks - Cambridge MA, US
Miles Stuart Congreve - Cambridge, GB
Claudio Dagostin - Cambridge, GB
Guo He - Cambridge MA, US
Ying Huo - Cambridge MA, US
Steven Howard - Cambridge, GB
Yue Li - Shanghai, CN
Yipin Lu - Cambridge MA, US
Paul Mortenson - Cambridge, GB
Troy Smith - Cambridge MA, US
Moo Je Sung - Cambridge MA, US
Steven Woodhead - San Diego CA, US
Wojciech Wrona - Cambridge MA, US
Christopher Thomas Brain - Cambridge MA, US
Clinton A. Brooks - Cambridge MA, US
Miles Stuart Congreve - Cambridge, GB
Claudio Dagostin - Cambridge, GB
Guo He - Cambridge MA, US
Ying Huo - Cambridge MA, US
Steven Howard - Cambridge, GB
Yue Li - Shanghai, CN
Yipin Lu - Cambridge MA, US
Paul Mortenson - Cambridge, GB
Troy Smith - Cambridge MA, US
Moo Je Sung - Cambridge MA, US
Steven Woodhead - San Diego CA, US
Wojciech Wrona - Cambridge MA, US
International Classification:
A61K 31/519
C07D 487/04
A61K 31/551
C12N 5/00
C07D 487/04
A61K 31/551
C12N 5/00
US Classification:
51421021, 544280, 540575, 544121, 544238, 51425216, 5142651, 514218, 435375
Abstract:
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
Pyrrolopyrimidine Compounds And Their Uses
US Patent:
2011015, Jun 23, 2011
Filed:
Aug 20, 2009
Appl. No.:
13/060154
Inventors:
Gilbert Besong - Cambridge, GB
Christopher Thomas Brain - Cambridge MA, US
Clinton A. Brooks - Cambridge MA, US
Miles Stuart Congreve - Cambridge, GB
Claudio Dagostin - Cambridge, GB
Guo He - Cambridge MA, US
Ying Huo - Cambridge MA, US
Steven Howard - Cambridge, GB
Yue Li - Shanghai, CN
Yipin Lu - Cambridge MA, US
Paul Morteson - Cambridge, GB
Troy Smith - Cambridge MA, US
Moo Sung - Cambridge MA, US
Steven Woodhead - Cambridge, GB
Wojciech Wrona - Cambridge MA, US
Christopher Thomas Brain - Cambridge MA, US
Clinton A. Brooks - Cambridge MA, US
Miles Stuart Congreve - Cambridge, GB
Claudio Dagostin - Cambridge, GB
Guo He - Cambridge MA, US
Ying Huo - Cambridge MA, US
Steven Howard - Cambridge, GB
Yue Li - Shanghai, CN
Yipin Lu - Cambridge MA, US
Paul Morteson - Cambridge, GB
Troy Smith - Cambridge MA, US
Moo Sung - Cambridge MA, US
Steven Woodhead - Cambridge, GB
Wojciech Wrona - Cambridge MA, US
Assignee:
NOVARTIS AG - Basel
ASTEX THERAPEUTICS LTD. - Cambridge
ASTEX THERAPEUTICS LTD. - Cambridge
International Classification:
C07D 487/04
A61K 31/497
A61K 31/519
A61K 31/551
A61K 31/5377
A61K 31/501
C12N 9/99
A61P 35/04
A61P 29/00
A61K 31/497
A61K 31/519
A61K 31/551
A61K 31/5377
A61K 31/501
C12N 9/99
A61P 35/04
A61P 29/00
US Classification:
51421021, 544280, 51425216, 5142651, 540575, 514218, 5142342, 544117, 51425202, 544238, 435184
Abstract:
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
Biodegradable Lipids For The Delivery Of Active Agents
US Patent:
2022037, Nov 24, 2022
Filed:
Sep 27, 2019
Appl. No.:
17/250952
Inventors:
- Cambridge MA, US
Guo He - Cambridge MA, US
Martin Maier - Cambridge MA, US
Guo He - Cambridge MA, US
Martin Maier - Cambridge MA, US
International Classification:
A61K 9/16
C07C 217/08
C07C 219/20
C07C 229/30
C12N 15/113
C07C 217/08
C07C 219/20
C07C 229/30
C12N 15/113
Abstract:
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Extrahepatic Delivery
US Patent:
2023001, Jan 19, 2023
Filed:
Nov 6, 2020
Appl. No.:
17/774477
Inventors:
- Cambridge MA, US
Martin A. MAIER - Cambridge MA, US
Juan C. SALINAS - Cambridge MA, US
Shigeo MATSUDA - Cambridge MA, US
Scott P. LENTINI - Cambridge MA, US
Guo HE - Cambridge MA, US
Michelle H. JUNG - Cambridge MA, US
Justin M. PIERSON - Cambridge MA, US
Muthiah MANOHARAN - Cambridge MA, US
Dale C. GUENTHER - Cambridge MA, US
Ivan ZLATEV - Cambridge MA, US
Christopher S. THEILE - Cambridge MA, US
Vasant R. JADHAV - Cambridge MA, US
Stuart MILSTEIN - Cambridge MA, US
Maja JANAS - Cambridge MA, US
Dhrubajyoti DATTA - Cambridge MA, US
Martin A. MAIER - Cambridge MA, US
Juan C. SALINAS - Cambridge MA, US
Shigeo MATSUDA - Cambridge MA, US
Scott P. LENTINI - Cambridge MA, US
Guo HE - Cambridge MA, US
Michelle H. JUNG - Cambridge MA, US
Justin M. PIERSON - Cambridge MA, US
Muthiah MANOHARAN - Cambridge MA, US
Dale C. GUENTHER - Cambridge MA, US
Ivan ZLATEV - Cambridge MA, US
Christopher S. THEILE - Cambridge MA, US
Vasant R. JADHAV - Cambridge MA, US
Stuart MILSTEIN - Cambridge MA, US
Maja JANAS - Cambridge MA, US
Dhrubajyoti DATTA - Cambridge MA, US
International Classification:
A61K 31/713
A61K 48/00
C12N 15/113
A61P 25/28
A61K 48/00
C12N 15/113
A61P 25/28
Abstract:
One aspect of the present invention relates to a compound comprising an antisense strand which is complementary to a target gene; a sense strand which is complementary to said antisense strand; and one or more lipophilic monomers, containing one or more lipophilic moieties, conjugated to one or more positions on at least one strand, optionally via a linker or carrier. Another aspect of the invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic monomer-conjugated compound.
Pyrrolopyrimidine Compounds And Their Uses
US Patent:
2021025, Aug 19, 2021
Filed:
Sep 16, 2020
Appl. No.:
17/023041
Inventors:
- Basel, CH
- Cambridge, GB
Clinton A. BROOKS - Durham NC, US
Miles Stuart CONGREVE - Royston, GB
Claudio DAGOSTIN - Cambridge, GB
Guo HE - Framingham MA, US
Ying HOU - Belmont MA, US
Steven HOWARD - Cambridge, GB
Yue LI - Ettingen, CH
Yipin LU - Dublin CA, US
Paul MORTENSON - Cambridge, GB
Troy SMITH - Nashua NH, US
Moo Je SUNG - Belmont MA, US
Steven WOODHEAD - San Diego CA, US
Wojciech WRONA - Waltham MA, US
Bharat LAGU - Acton MA, US
- Cambridge, GB
Clinton A. BROOKS - Durham NC, US
Miles Stuart CONGREVE - Royston, GB
Claudio DAGOSTIN - Cambridge, GB
Guo HE - Framingham MA, US
Ying HOU - Belmont MA, US
Steven HOWARD - Cambridge, GB
Yue LI - Ettingen, CH
Yipin LU - Dublin CA, US
Paul MORTENSON - Cambridge, GB
Troy SMITH - Nashua NH, US
Moo Je SUNG - Belmont MA, US
Steven WOODHEAD - San Diego CA, US
Wojciech WRONA - Waltham MA, US
Bharat LAGU - Acton MA, US
International Classification:
C07D 487/04
C07D 487/08
A61K 31/519
A61P 35/00
C07D 487/08
A61K 31/519
A61P 35/00
Abstract:
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
Chirally-Enriched Double-Stranded Rna Agents
US Patent:
2021020, Jul 8, 2021
Filed:
Dec 21, 2018
Appl. No.:
16/956271
Inventors:
- Cambridge MA, US
Nate TANEJA - Cambridge MA, US
Hartmut Ingo JAHNS - Cambridge MA, US
Shigeo MATSUDA - Cambridge MA, US
Klaus CHARISSE - Cambridge MA, US
Guo HE - Cambridge MA, US
Jayaprakash K. NAIR - Cambridge MA, US
Christopher BROWN - Cambridge MA, US
Mark K. SCHLEGEL - Cambridge MA, US
Vasant JADHAV - Cambridge MA, US
Martin MAIER - Cambridge MA, US
Nate TANEJA - Cambridge MA, US
Hartmut Ingo JAHNS - Cambridge MA, US
Shigeo MATSUDA - Cambridge MA, US
Klaus CHARISSE - Cambridge MA, US
Guo HE - Cambridge MA, US
Jayaprakash K. NAIR - Cambridge MA, US
Christopher BROWN - Cambridge MA, US
Mark K. SCHLEGEL - Cambridge MA, US
Vasant JADHAV - Cambridge MA, US
Martin MAIER - Cambridge MA, US
International Classification:
C12N 15/113
Abstract:
The present invention relates to a chirally-modified dsRNA agent capable of inhibiting the expression of a target gene. The sense and antisense strands of chirally-modified dsRNA agent independently or in combination comprises one or more site specific-site specific/position specific, chirally-modified internucleotide linkages.
Benzothiophene Derivatives And Compositions Thereof As Selective Estrogen Receptor Degraders
US Patent:
2018016, Jun 21, 2018
Filed:
Feb 17, 2018
Appl. No.:
15/898561
Inventors:
- Basel, CH
Michael A. DECHANTSREITER - Cambridge MA, US
Guo HE - Cambridge MA, US
Jill NUNEZ - Cambridge MA, US
Stefan PEUKERT - Cambridge MA, US
Clayton SPRINGER - Cambridge MA, US
Yingchuan SUN - Cambridge MA, US
Noel Marie-France THOMSEN - Cambridge MA, US
George Scott TRIA - Cambridge MA, US
Bing YU - Cambridge MA, US
Michael A. DECHANTSREITER - Cambridge MA, US
Guo HE - Cambridge MA, US
Jill NUNEZ - Cambridge MA, US
Stefan PEUKERT - Cambridge MA, US
Clayton SPRINGER - Cambridge MA, US
Yingchuan SUN - Cambridge MA, US
Noel Marie-France THOMSEN - Cambridge MA, US
George Scott TRIA - Cambridge MA, US
Bing YU - Cambridge MA, US
International Classification:
A61K 31/381
A61K 45/06
C07D 409/04
A61K 31/4436
A61K 31/4245
A61K 31/422
A61K 31/4196
C07D 413/12
C07D 413/04
C07D 409/12
C07D 333/66
C07D 333/64
A61K 31/5377
A61K 31/404
A61K 31/41
A61K 31/428
A61K 31/397
A61K 31/4025
A61K 31/4745
C07D 417/12
C07D 409/10
A61K 31/506
A61K 45/06
C07D 409/04
A61K 31/4436
A61K 31/4245
A61K 31/422
A61K 31/4196
C07D 413/12
C07D 413/04
C07D 409/12
C07D 333/66
C07D 333/64
A61K 31/5377
A61K 31/404
A61K 31/41
A61K 31/428
A61K 31/397
A61K 31/4025
A61K 31/4745
C07D 417/12
C07D 409/10
A61K 31/506
Abstract:
The present invention relates to compounds of formula I:
Pyrrolopyrimidine Compounds And Their Uses
US Patent:
2018015, Jun 7, 2018
Filed:
Feb 1, 2018
Appl. No.:
15/886014
Inventors:
- Basel, CH
- Cambridge, GB
Clinton A. Brooks - Durham NC, US
Miles Stuart Congreve - Cambridge, GB
Claudio Dagostin - Cambridge, GB
Guo He - Framingham MA, US
Ying Hou - Cambridge MA, US
Steven Howard - Cambridge, GB
Yue Li - Shanghai, CN
Yipin Lu - Emeryville CA, US
Paul Mortenson - Cambridge, GB
Troy Smith - Cambridge MA, US
Moo Je Sung - Cambridge MA, US
Steven Woodhead - Cambridge, GB
Wojciech Wrona - Cambridge MA, US
Bharat Lagu - Acton MA, US
- Cambridge, GB
Clinton A. Brooks - Durham NC, US
Miles Stuart Congreve - Cambridge, GB
Claudio Dagostin - Cambridge, GB
Guo He - Framingham MA, US
Ying Hou - Cambridge MA, US
Steven Howard - Cambridge, GB
Yue Li - Shanghai, CN
Yipin Lu - Emeryville CA, US
Paul Mortenson - Cambridge, GB
Troy Smith - Cambridge MA, US
Moo Je Sung - Cambridge MA, US
Steven Woodhead - Cambridge, GB
Wojciech Wrona - Cambridge MA, US
Bharat Lagu - Acton MA, US
International Classification:
C07D 487/04
A61K 31/519
A61K 31/519
Abstract:
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.